Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery

Hoener, 1996, Factors influencing drug absorption and drug availability, 121 Rowland, 1995, Clinical Pharmacokinetics: Concepts and Applications, 119 Tam, 1993, Individual variation in first-pass metabolism, Clin. Pharmacokinet., 25, 300, 10.2165/00003088-199325040-00005 Thiebaut, 1987, Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues, 84, 7735 Watkins, 1987, Identification of glucocorticoid-inducible cytochromes P-450 in intestinal mucosa of rats and man, J. Clin. Invest., 80, 1029, 10.1172/JCI113156 Kolars, 1992, Identification of rifampin-inducible P450IIIA4 (CYP 3A4) in human small bowel enterocytes, J. Clin. Invest., 90, 1871, 10.1172/JCI116064 Kolars, 1991, First-pass metabolism of cyclosporin by the gut, Lancet, 338, 1488, 10.1016/0140-6736(91)92302-I Wacher, 1995, Overlapping substrate specificities and tissue distribution of cytochrome P-450 3A and P-glycoprotein have implications for drug delivery and activity in cancer chemotherapy, Mol. Carcinog., 13, 129, 10.1002/mc.2940130302 Wu, 1993, Use of i.v. and oral drug levels from cyclosporine (CsA) with concomitant rifampin to differentiate gut absorption and metabolism, Pharm. Res., 10, S345 Wu, 1995, Differentiation of absorption, first-pass gut and hepatic metabolism in man: studies with cyclosporine, Clin. Pharmacol. Ther., 58, 492, 10.1016/0009-9236(95)90168-X Hebert, 1992, Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction, Clin. Pharmacol. Ther., 52, 453, 10.1038/clpt.1992.171 Gomez, 1995, The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine, Clin. Pharmacol. Ther., 58, 15, 10.1016/0009-9236(95)90067-5